DTx Pharma to Present at the Chardan Virtual 4th Annual Genetic Medicines Event

Prnewswire | September 29, 2020

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and will participate in 1x1 meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th, 2020 at 4:45 pm EDT. "At DTx, we are focused on treating the genetic drivers of disease by applying our FALCON technology platform to expand the therapeutic utility of oligonucleotides," said Dr. Suckow. "We look forward to presenting our company at the Chardan Genetic Medicines event and demonstrating the disruptive potential of our FALCON platform in creating the next wave of RNA-based therapeutics."

Spotlight

The FTC's recent $1.2 billion settlement over the drug Provigil has brought so-called "pay for delay" deals for generic drugs back into the spotlight. Opponents say these deals delay generic medications to market, costing consumers billions. But drug companies say that the deals help get generics to market by avoiding lengthy patent litigation. NewsHour's Megan Thompson reports.

Spotlight

The FTC's recent $1.2 billion settlement over the drug Provigil has brought so-called "pay for delay" deals for generic drugs back into the spotlight. Opponents say these deals delay generic medications to market, costing consumers billions. But drug companies say that the deals help get generics to market by avoiding lengthy patent litigation. NewsHour's Megan Thompson reports.

Related News

PHARMA TECH

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research

Invitae | September 07, 2021

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making. "Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe. We believe combining Ciitizen's state-of-the-art, transparent and patient-consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one's life. This would give us the ability to engage patients, create an innovative patient-centered data ecosystem and deliver better outcomes for everyone. Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces," said Sean George, Ph.D., co-founder and CEO of Invitae. "Ciitizen has already helped patients take ownership of their medical records to optimize therapy for themselves and contribute their data towards a variety of goals, including research on rare diseases," said Anil Sethi, CEO and founder of Ciitizen. "Patients leave a breadcrumb trail of records behind them, and we believe access to this real-world data is key to personalized therapeutics in the future. The combination of lifelong health history together with Invitae's world-class genetic and data services would enable a digital ecosystem of personalized services for each patient. Democratization of patient-consented data is expected to improve outcomes by providing access to third-parties for whom the patient has granted consent. Unlike many health data companies, we operate on the premise that it's the patient's data, not ours." Invitae is working to aggregate results from the world's genetic tests into a single, easy-to-use service that makes genetic information accessible to all who can benefit from it - always with patient consent. Over the past five years, Invitae has completed 13 acquisitions that have expanded its testing menu, lowered the cost of its tests, improved its customer experience and enhanced its ability to attract partners. Invitae raised more than $1.4 billion since the beginning of 2021, in part to identify and acquire key assets that bring the company closer to delivering on its vision. The addition of Ciitizen is expected to empower Invitae to more quickly extend its platform, adding a complementary patient service that streamlines the process of collecting and organizing health information from any source and uses machine learning to transform the unstructured (and largely untapped) health information to enable better care decisions, find clinical trials, and power research using real-world evidence. In addition, as the use of Invitae testing and the Ciitizen service expands, third-party access to consented genomic and other clinical data can be democratized to power a variety of applications that can enhance Invitae's business and growth strategy. About Invitae Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. About Ciitizen Ciitizen is a patient-centric consumer health technology platform that enables patients to collect, store and share their medical records in a single location. Ciitizen developed proprietary machine learning and AI technologies to abstract critical information from unstructured health records to advance the understanding of diseases, match patients with potentially life-saving clinical trials, and enable better care decisions. Ciitizen also provides valuable big data analytics and data quality technologies to the network of Health Information Exchanges (HIEs) to produce research-ready, regulatory-grade data within minutes, instead of hours or days, and ensure HIEs can comply with the Information Blocking regulations.

Read More

Apricus Health Partners with Medicare Advantage Plan Devoted Health and Full-Service Retail Pharmacy Liton Rx

Apricus Health | November 04, 2020

Apricus Health, an innovative healthcare company delivering high impact, relationship-based care, today announced two new partnerships that provide its members with extraordinary services. Medicare Advantage plan provider Devoted Health and full-service retail pharmacy Liton Rx are now partnering with the Apricus Health Network which is designed by Arizona physicians. "We are committed to helping our members with a range of quality services to improve health outcomes and significantly lower costs for patients and payers," said Dr. Kishlay Anand, CEO and co-founder of Apricus Health. "Our new partnerships with Devoted Health and Liton Rx, further that mission, with both organizations sharing our core value of emphasizing extraordinary customer service."

Read More

New GSK campaign works to raise adult vaccine awareness—and counter COVID-19 slump

Fiercepharma | August 27, 2020

GlaxoSmithKline has a goal when it comes to vaccine awareness: Boost education enough so that when people turn 50, they recognize age-recommended vaccines as automatically as they know it's time to get a colonoscopy. To work toward that benchmark, the company debuted its first general vaccine awareness campaign in the U.S. this month. The multichannel effort keys in on life moments, with the message that they’re made possible by vaccines. The “Brought to You by Vaccines” campaign includes TV, digital, social media and public relations and will run through mid-2021.

Read More